Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Secu

Delivering the Power of Sight Investor

Presentation December 2021 Exhibit 99.1

1 Forward Looking Statements This

presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the

Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and

includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this presentation or during the earnings call that are not statements of historical fact, including statements about our beliefs and

expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies.

These statements often include words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets,"

"projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. We base these forward-looking statements on our current

expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under

the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and

financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. The forward-looking statements are subject to and

involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: estimates of our total

addressable market, future revenue, expenses, capital requirements, and our needs for additional financing; our ability to enter into and compete in new markets; execution of our market strategies; the impact of the COVID-19 pandemic on our

business, our customers' and suppliers' businesses and the general economy; our ability to compete effectively with existing competitors and new market entrants; our ability to scale our infrastructure; our ability to manage and grow our

business by expanding our sales to existing customers or introducing our products to new customers; our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement; potential effects of

extensive government regulation; our abilities to obtain and maintain regulatory approvals and clearances for our products that support our business strategies and growth; our ability to successfully execute our clinical trial roadmap our ability to

obtain and maintain sufficient reimbursement for our products; our abilities to protect and scale our intellectual property portfolio; our ability to hire and retain key personnel; our ability to obtain financing in future offerings; the volatility

of the trading price of our common stock; our expectation regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (the "JOBS Act"); and our ability to maintain proper and

effective internal controls. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether

as a result of new information, future events or otherwise, except as required by applicable law. Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third-party

sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or

completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability

of such assumptions. Finally, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source. We have proprietary rights to trademarks, trade names and service

marks appearing in this presentation that are important to our business. Solely for convenience, the trademarks, trade names and service marks may appear in this presentation without the and symbols, but any such references are not

intended to indicate, in any way, that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and

service marks appearing in this presentation are the property of their respective owners. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed

to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Without limitation, SIGHT SCIENCES , OMNI , and TEARCARE are trademarks of Sight Sciences, Inc. in the United States and other

2 Transform Ophthalmology and Optometry

through products that target the underlying causes of the world's most prevalent eye diseases Establish new treatment paradigms and create an interventional mindset in Eyecare to replace conventional outdated approaches Our Mission

Our World Class Team 3 Paul Badawi

Chief Executive Officer and Co-Founder Dr. David Badawi, MD Chief Technology Officer and Co-Founder Jesse Selnick Chief Financial Officer Shawn O'Neil Chief Commercial Officer Sam Park Chief Operating Officer Jeremy Hayden Chief Legal Officer

Dr. Reay Brown, MD Chief Medical Officer Prominent ophthalmologist and inventor of much of the IP in MIGS Kavita Dhamdhere, MD, PhD Vice President, Clinical Development Stacie Rodgers Vice President, Human Resources Tom Huang Head of Corporate

Strategy and Development John Liu Senior Vice President, Global Market Access Kathy Chester Vice President, Regulatory Affairs

4 Four fundamental requirements to

deliver consistent, effective and safe outcomes for patients Our Product Development Process Comprehensive Understanding of Disease Physiology Analyze available clinical data, science and literature to achieve sound understanding of disease Address

the Underlying Causes Developing and marketing products designed to restore natural functionality of diseased eyes for optimal combination of effectiveness and safety Intuitive Design Innovate with intuitive, minimally invasive, user-friendly

"go to" solutions and procedures for eyecare providers (ECPs) Patient Access Maximize availability and accessibility of solutions to patients with a data-driven approach and clinical rigor

5 Developing and Commercializing

Products That We Believe Will Disrupt Two Major Eyecare Categories Large, unmet market need Differentiated, innovative, intuitive design Robust clinical data Maximized patient access Comprehensive IP protection Demonstrated growth & strong

Micro-invasive Glaucoma Surgery (MIGS)

in POAG Launched in February 2018 Wearable eyelid technology to deliver targeted heat to meibomian glands (in development for dry eye disease3) Controlled release in April 2019 U.S. TAM1 of 2020 Revenue $6Bn 94% 66 Global Patents and Patent

Applications2 (47 issued, 19 pending) U.S. TAM1 of 2020 Revenue $10Bn 6% 31 Global Patents and Patent Applications2 (17 issued, 14 pending) Company estimate for 2020 As of November 30, 2021 FDA 510k to expand indication for use submitted September

2021 Unlocking the Standalone MIGS Market Expanding Patient Access >80,000 OMNI cases performed to date2 >15,000 TearCare cases performed to date2 6 Products Designed to be Category-Defining

7 Strategic Value Creation Initiatives

Expand Presence in Established Combination Cataract MIGS Segment in POAG Continue gaining adoption among existing base of >3,000 MIGS-trained surgeons Continue taking share by leveraging the ability of OMNI to address all three points of

potential resistance in the conventional outflow pathway Compelling growth opportunity: $1BN Combination Cataract segment is ~1/3 penetrated Combination Cataract clinical trials Develop and Grow Underserved Standalone MIGS Segment in POAG

Significant untapped opportunity in 5x larger Standalone MIGS segment Expand use by existing OMNI-trained surgeons from Combination Cataract cases to Standalone cases Educate primary care ophthalmologists and optometrists, who typically first

diagnose and treat POAG, that a mild-to-moderate Standalone MIGS procedure is available and help connect with local OMNI-trained surgeons Standalone clinical trials Develop Market Access for TearCare Procedures Long term strategy with multiple

complementary elements SAHARA RCT versus Restasis - designed with input from eight payor medical directors to demonstrate effectiveness and durability Real-world claims submissions Seeking FDA clearance for expanded indication for use in

meibomian gland dysfunction and dry eye disease Convert existing Category III CPT code (0563T) to permanent Category I code

Primary Open-Angle Glaucoma

Glaucoma is world's leading

cause of irreversible blindness POAG is the most prevalent form of glaucoma No cure and progressive Steadily growing patient base Improving diagnostics Aging populations Demographic shifts Growth of comorbidities such as diabetes, heart disease and

high blood pressure In primary open-angle glaucoma (POAG), aqueous humor builds up in the anterior chamber of the eye 8 4.1 million U.S. sufferers 3.4 million U.S. diagnosed 60 million WW sufferers POAG prevalence Resultant tension can interfere

with blood supply to the optic nerve, leading to optic nerve cell death and irreversible vision loss Elevated intraocular pressure (IOP) is one of the greatest and the only controllable risk factor of POAG Primary Open-Angle Glaucoma: A Large,

9 Current Global POAG Treatment

Market Rx medications currently have the supermajority of treatment share (estimated >80%) Conventional surgery has been a last line therapy MIGS are transforming POAG treatment, but still well underpenetrated (estimated <10%) Fastest growing

treatment segment (25%-37% est. W.W. 2020-2025 CAGR) Growth driven by fast recovery times, attractive safety profile, low rate of side effects Disproportionately performed in combination with cataract surgery today since trabecular bypass stents

(which are only indicated for use in combination with cataract surgery in the U.S.) were first MIGS entrants Our definition of MIGS = minimally invasive glaucoma procedures utilizing an ab interno approach though a single, clear corneal

10 U.S. MIGS Total Addressable

Market 4.2 million people U.S. population with POAG and PEX (pseudoexfoliation glaucoma) 3.5 million people U.S. population diagnosed with POAG and PEX 3.4 million people U.S. population diagnosed with POAG 6.2 million eyes with POAG in the U.S. ~$6

billion U.S. TAM for POAG Assumes average 2020 ASP for MIGS devices Assumes 80% bilateral prevalence (1.8x multiplier) PEX estimated to account for 0-6% of combined POAG / PEX glaucoma (assumes 3% midpoint) Enormous market development opportunity

2020 U.S. surgical glaucoma device manufacturer revenues only ~$350 million

11 POAG Treatment Paradigm

PRESCRIPTION MEDICATIONS OMNI is designed to expand MIGS reach and impact and enable a new interventional treatment paradigm STANDALONE (85%1 of POAG) COMBINATION CATARACT (15%1 of POAG) CONVENTIONAL TREATMENTS TRABECULAR BYPASS STENTS LASER

TRABECULOPLASTY CONVENTIONAL SURGERY MILD (~40%) MODERATE (~40%) ADVANCED (~20%) Represents % of U.S. POAG patients 1 1 1 ALTERNATIVE BYPASS STENTS MIGS

Combination Cataract (<15% of

POAG eyes) Concurrent MIGS and cataract procedure Benefits from inherent IOP-lowering effect of cataract surgery First-mover trabecular bypass stents are only authorized for use in Combination Cataract cases Has skewed MIGS towards this segment

Standalone (>85% of POAG eyes) Large, underdeveloped and underpenetrated MIGS procedure the primary reason for patient to be brought into the OR Standalone adoption and growth require strong and highly consistent effectiveness, particularly

without the benefit of concurrent cataract surgery 12 "Standalone" = Extending MIGS to All POAG >85% Eyes Treated in 2019 Total U.S. eyes diagnosed with POAG 6,156,000 Estimated eyes receiving cataract surgery which also had glaucoma

/ OHT 774,000 Eyes in potential U.S. Standalone market 5,382,000 - =

13 We believe (i) there is NO

diagnostic to determine where the resistance is in the conventional outflow pathway and (ii) OMNI is singularly well-suited to address all 3 primary points of resistance OMNI Addresses the 3 Primary Points of Resistance TRABECULAR

MESHWORK SCHLEMM'S CANAL COLLECTOR CHANNELS Trabecular Bypass Stents Canaloplasty Only Trabeculotomy Only 1 2 3 1 2 3 TRABECULAR MESHWORK SCHLEMM'S CANAL DISTAL COLLECTOR CHANNELS Canaloplasty using OMNI expands and dilates

Schlemm's canal and collector channels We believe OMNI is singularly well-suited among MIGS devices to comprehensively address all 3 primary points of resistance in the conventional outflow pathway Trabeculotomy using OMNI unroofs the

14 OMNI : Cleared for Use in a

Revolutionary MIGS Procedure in All Adult Patients with POAG OMNI enables two sequential, ab interno MIGS procedures in adults with POAG - intuitive, minimally invasive, performed through a single clear corneal microincision, and each

titratable up to 360 Trabeculotomy using OMNI Canaloplasty using OMNI Device Cleared for Use as an Efficient, Titratable Approach to Two Proven, Effective Procedures Conventional ab externo canaloplasty and trabeculotomy procedures are

effective, but invasive (require deep scleral incisions) and associated with complications and longer recovery times Schlemm's Canal Schlemm's Canal Trabecular Meshwork Trabecular Meshwork Collector Channels Cannula Tip Cannula Tip

Microcatheter Microcatheter Clear Corneal Microincision Clear Corneal Microincision Collector Channels

15 OMNI is Titratable to All 6

MIGS Categories in POAG Low Risk of Hyphema Consistency of Efficacy Degree of Efficacy Represents % of U.S. POAG TAM The FDA granted an investigational device exemption authorizing our PRECISION RCT to assess the safety and effectiveness of a

canaloplasty alone procedure in conjunction with cataract surgery Mild Disease (40%)1 Moderate Disease (40%)1 Advanced Disease (20%)1 Primary Distinguishing Treatment Requirements for MIGS Procedures: 360 Canaloplasty2 360 Canaloplasty

90 - 180 Trab 360 Canaloplasty 90 - 180 Trab 360 Canaloplasty 180 Trab 360 Canaloplasty 180 - 360 Trab 360 Canaloplasty 360 Trab Combination Cataract MIGS <15%1 Standalone

16 FDA-Cleared IFU of OMNI

Supports Strong Market Positioning March 2021 Indication for Use "For canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular

pressure (IOP) in adult patients with primary open-angle glaucoma" OMNI is the only device cleared by the FDA based on clinical data using an ab interno approach that can: Reduce IOP in adult patients with POAG across the spectrum of

disease severity Reduce IOP in adult patients with POAG across the spectrum of disease severity Be used in Mild-to-Moderate Combination Cataract or Standalone procedures Access 360 degrees of the diseased conventional outflow pathway through a

single clear corneal microincision Comprehensively address all three points of resistance in the conventional outflow pathway in a single outpatient visit

Unique go-to-market strategy to

pioneer $5B Standalone segment with MIGS Surgeons Commercial team structured to unlock Standalone segment Surgical Sales Representatives: territory-based account coverage Strategic Account Managers: teaching institutions, government Glaucoma

Clinical Consultants (new): educate POAG primary care providers about Standalone MIGS Significant commercial team expansion planned in 2022 START: activate new accounts with MIGS-trained surgeons; first OMNI CC procedures GROW: train and support

with exceptional customer experience; gain skill and confidence in efficacy and consistency of OMNI EXPAND: fully confident in efficacy and skill to perform cases in CC and Standalone OMNI procedures; actively seeking standalone patients and

expanding use case within cleared indication Standalone Procedures ($5B potential market) Combination Cataract Procedures ($1B potential market) Activation Auditing Adoption/ Advocacy Expansion Adoption/ Advocacy 17 OMNI Commercial Strategy Weeks

The MIGS Surgeon's Journey

18 ROMEO data (published) and single

surgeon data sets report consistent IOP reduction in real-world settings Pooled data from 4 studies in 5 peer-reviewed publications Observed lower IOP in 98 of 103 patients (95%) Observed 20% decrease in IOP in 77 of 103 patients (75%) For

all eyes where preoperative IOP was 15 mmHg, observed lower IOP in 94 of 96 (98%) Pooled OMNI Data Across Multiple Clinical Studies: Consistent IOP Reduction Consistency is critical for Standalone market development as OMNI procedure

would be the sole purpose of patient's operating room visit Postoperative Target IOP